Your browser is no longer supported. Please, upgrade your browser.
TBPH Theravance Biopharma, Inc. daily Stock Chart
TBPH [NASD]
Theravance Biopharma, Inc.
Index- P/E- EPS (ttm)-4.00 Insider Own5.90% Shs Outstand62.58M Perf Week-6.26%
Market Cap1.47B Forward P/E- EPS next Y-3.48 Insider Trans-0.03% Shs Float49.17M Perf Month-9.09%
Income-221.00M PEG- EPS next Q-1.13 Inst Own73.10% Short Float5.88% Perf Quarter33.58%
Sales59.70M P/S24.64 EPS this Y26.70% Inst Trans-3.09% Short Ratio7.05 Perf Half Y10.95%
Book/sh-3.27 P/B- EPS next Y15.90% ROA-43.60% Target Price35.38 Perf Year-7.15%
Cash/sh5.11 P/C4.60 EPS next 5Y- ROE182.30% 52W Range15.18 - 31.54 Perf YTD-9.19%
Dividend- P/FCF- EPS past 5Y3.80% ROI-56.70% 52W High-27.17% Beta1.66
Dividend %- Quick Ratio- Sales past 5Y205.70% Gross Margin98.90% 52W Low51.32% ATR1.42
Employees363 Current Ratio3.30 Sales Q/Q-3.10% Oper. Margin- RSI (14)32.34 Volatility7.11% 4.94%
OptionableYes Debt/Eq- EPS Q/Q4.50% Profit Margin- Rel Volume1.25 Prev Close23.51
ShortableYes LT Debt/Eq- EarningsFeb 24 AMC Payout- Avg Volume410.10K Price22.97
Recom2.20 SMA20-16.10% SMA50-10.39% SMA20011.51% Volume359,522 Change-2.30%
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-06-19Upgrade Robert W. Baird Underperform → Neutral $22 → $18
Oct-29-19Initiated H.C. Wainwright Buy $25
Mar-29-18Resumed Piper Jaffray Overweight $45
Aug-17-17Initiated Evercore ISI Outperform $45
Jun-16-17Initiated Cantor Fitzgerald Overweight $55
May-11-17Reiterated Needham Buy $40 → $45
Dec-21-16Initiated Needham Buy $40
Nov-03-16Initiated Piper Jaffray Overweight
Oct-12-16Downgrade Robert W. Baird Neutral → Underperform $19 → $24
Aug-03-16Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16Reiterated Leerink Partners Outperform $26 → $29
Jun-20-16Initiated Guggenheim Buy $30
May-12-16Initiated Leerink Partners Outperform $26
May-05-16Downgrade BofA/Merrill Buy → Neutral
Feb-03-15Upgrade Robert W. Baird Underperform → Neutral $13 → $17
Aug-14-14Downgrade Robert W. Baird Neutral → Underperform $21
Feb-25-20 02:06AM  Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-24-20 06:15PM  Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.77%
Feb-18-20 07:00AM  Theravance Biopharma Announces Presentations at Upcoming Investor Conferences PR Newswire
Feb-17-20 12:30PM  Analysts Estimate Theravance Biopharma (TBPH) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-11-20 11:05PM  Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares PR Newswire -8.80%
02:21PM  How Does Investing In Theravance Biopharma, Inc. (NASDAQ:TBPH) Impact The Volatility Of Your Portfolio? Simply Wall St.
Feb-05-20 10:27AM  Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Jan-19-20 09:13AM  3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-07-20 04:48PM  Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-19 09:16AM  AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod Zacks
Dec-23-19 08:15AM  Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program PR Newswire
Dec-22-19 11:10AM  Hedge Funds Have Never Been Less Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Dec-10-19 12:22PM  Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-05-19 11:31AM  Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 07:50AM  Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Nov-26-19 04:15PM  Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Nov-09-19 10:43AM  Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-19 04:30PM  Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference PR Newswire
11:19AM  Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates Zacks
Nov-05-19 06:35PM  Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
11:24AM  What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
Oct-29-19 04:15PM  Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5 PR Newswire
10:32AM  Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-28-19 05:49PM  Here is What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey
Oct-21-19 04:00PM  Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting PR Newswire
Oct-07-19 10:25AM  Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Oct-02-19 01:34PM  Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares? Simply Wall St.
07:05AM  AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
Sep-25-19 04:05PM  Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-23-19 01:16PM  Seth Klarman Further Increases Translate Bio Stake GuruFocus.com
Sep-10-19 01:58PM  Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +8.88%
11:46AM  Theravance Announces Positive Early Data on JAK Inhibitor Zacks
Sep-09-19 07:05AM  Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Aug-28-19 04:30PM  Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-11-19 08:32AM  How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-09-19 08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 09:18AM  Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2 Zacks
Aug-02-19 05:44PM  Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 03:37PM  Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates Zacks
Jul-31-19 03:27PM  Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript Motley Fool
08:35AM  Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM  Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Jul-22-19 08:05AM  Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress PR Newswire
Jul-18-19 02:33PM  New antibiotics desperately needed for rising tide of drug-resistant superbugs American City Business Journals
Jun-27-19 11:27AM  How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year? Simply Wall St.
Jun-25-19 07:42AM  Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium MarketWatch
Jun-20-19 09:18AM  AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod Zacks
Jun-18-19 09:00AM  Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress PR Newswire
Jun-17-19 03:31PM  Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years Simply Wall St.
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 08:05AM  Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories PR Newswire
Jun-06-19 09:31AM  Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-04-19 08:30AM  Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer PR Newswire
May-22-19 09:50AM  Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks
May-21-19 07:01AM  Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-20-19 10:15AM  Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference PR Newswire
May-14-19 11:39PM  Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript Motley Fool
02:21PM  Edited Transcript of TBPH earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
08:30AM  Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-08-19 11:44AM  Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates Zacks -9.49%
May-07-19 07:15PM  Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:12PM  Theravance Bio: 1Q Earnings Snapshot Associated Press
04:05PM  Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
May-02-19 01:20PM  Heres What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey +6.52%
Apr-30-19 04:05PM  Theravance Biopharma to Report First Quarter 2019 Financial Results on May 7 PR Newswire
Apr-24-19 08:56AM  Read This Before Buying Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Simply Wall St.
Apr-02-19 08:30AM  Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference PR Newswire
Mar-28-19 09:30AM  Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report? Zacks
Mar-25-19 08:30AM  Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress PR Newswire
Mar-13-19 02:27PM  Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study Zacks +5.17%
Mar-12-19 08:30AM  Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis PR Newswire
Mar-07-19 12:45PM  Edited Transcript of TBPH earnings conference call or presentation 26-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-27-19 12:48PM  Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates Zacks
Feb-26-19 09:35PM  Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
03:00PM  Theravance Biopharma Inc to Host Earnings Call ACCESSWIRE
Feb-21-19 08:30AM  Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire -6.22%
07:45AM  Frontier Communications' (FTR) Q4 Earnings: What's in Store? Zacks
Feb-19-19 06:36PM  /C O R R E C T I O N -- Theravance Biopharma, Inc./ PR Newswire
08:39AM  Will Leasing Support SBA Communications' (SBAC) Q4 Earnings? Zacks
Feb-18-19 08:23AM  What's in Store for Telefonica Brasil (VIV) in Q4 Earnings? Zacks
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals
Jan-28-19 08:30AM  Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension PR Newswire
Jan-27-19 08:44PM  Edited Transcript of TBPH earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Jan-23-19 08:47AM  With $500M in reserve, biotech cuts 49 jobs to focus on maturing drug pipeline American City Business Journals
Jan-08-19 02:25PM  Should You Worry About Theravance Biopharma, Inc.s (NASDAQ:TBPH) CEO Pay Cheque? Simply Wall St.
Jan-07-19 12:36PM  Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities PR Newswire
Dec-04-18 08:30AM  Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York PR Newswire
Dec-03-18 08:30AM  Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes PR Newswire
Nov-29-18 04:47PM  Theravance Pipeline Strong, Plans Yupelri Launch by Year End Zacks
Nov-28-18 10:20AM  Theravance's Respiratory Disease JAK Inhibitor Enters Phase I Zacks +5.65%
Nov-27-18 07:55AM  Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor PR Newswire
Nov-21-18 11:15AM  Theravance JAK Inhibitor Enters Phase II for Crohn's Disease Zacks
Nov-20-18 04:25PM  IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses Investor's Business Daily -5.49%
08:30AM  Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease PR Newswire
Nov-19-18 08:30AM  Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SABESAN VIJAYSVP, Technical OperationsDec 12Sale21.031,02721,598145,253Dec 16 06:09 PM
O'Connor DonalDirectorMay 17Sale20.192,67353,96827,571May 20 06:02 PM
O'Connor DonalDirectorMay 16Sale21.001,32727,86730,244May 20 06:02 PM
HEGDE SHARATHCHANDRA SSVP, ResearchMar 05Sale24.505,690139,405264,444Mar 06 07:20 PM
HEGDE SHARATHCHANDRA SSVP, ResearchMar 04Sale25.063,34383,764270,134Mar 06 07:20 PM